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ABSTRACT
Objective: To further determine the causes of variable outcome from deep brain stimulation of the
subthalamic nucleus (DBS-STN) in patients with Parkinson disease (PD).
Methods: Data were obtained from our cohort of 309 patients with PD who underwent DBS-STN
between 1996 and 2009. We examined the relationship between the 1-year motor, cognitive,
and psychiatric outcomes and (1) preoperative PD clinical features, (2) MRI measures, (3) surgical
procedure, and (4) locations of therapeutic contacts.
Results: Pre- and postoperative results were obtained in 262 patients with PD. The best motor
outcome was obtained when stimulating contacts were located within the STN as compared with
the zona incerta (64% vs 49% improvement). Eighteen percent of the patients presented a post-
operative cognitive decline, which was found to be principally related to the surgical procedure.
Other factors predictive of poor cognitive outcome were perioperative confusion and psychosis.
Nineteen patients showed a stimulation-induced hypomania, which was related to both the form
of the disease (younger age, shorter disease duration, higher levodopa responsiveness) and the
ventral contact location. Postoperative depression was more frequent in patients already show-
ing preoperative depressive and/or residual axial motor symptoms.
Conclusion: In this homogeneous cohort of patients with PD, we showed that (1) the STN is the
best target to improve motor symptoms, (2) postoperative cognitive deficit is mainly related to
the surgery itself, and (3) stimulation-induced hypomania is related to a combination of both
the disease characteristics and a more ventral STN location. Neurology® 2014;82:1352–1361
GLOSSARY
ADL5 activities of daily living;AS5 associative;DBS5 deep brain stimulation;DSM-IV5Diagnostic and Statistical Manual
of Mental Disorders, 4th edition;MADRS5Montgomery-Åsberg Depression Rating Scale;MDRS5Mattis Dementia Rating
Scale; PD 5 Parkinson disease; SM 5 sensorimotor; STN 5 subthalamic nucleus; UPDRS 5 Unified Parkinson’s Disease
Rating Scale; ZI 5 zona incerta.
Bilateral deep brain stimulation of the subthalamic nucleus (DBS-STN) has been shown to dra-
matically alleviate motor symptoms in patients with Parkinson disease (PD).1 However, some
patients show poor relief of parkinsonian motor disability and/or nonmotor side effects, such as
a dysexecutive syndrome2 or psychiatric symptoms.3 These side effects impair the postsurgery
quality of life and are responsible for a poor global outcome.4,5 Because of these postoperative
problems, some authors have (re)proposed other targets such as the globus pallidus interna6,7 or
the zona incerta (ZI).8
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Several preoperative clinical factors are pre-
dictive of some of the postoperative difficulties
with DBS-STN: (1) older age, (2) parkinson-
ism with poor response to dopaminergic treat-
ment,9 (3) preoperative cognitive deficit such
as executive dysfunction,2 or (4) focal brain
atrophy.10 Ventral location of the STN stim-
ulating contact may provoke transient postsur-
gical hypomania.11,12 The role of preoperative
factors,13 surgical procedure,14,15 locations of
stimulating contacts,16,17 and postoperative
management18 on the postoperative motor
benefit and side effects has already been inde-
pendently studied in small cohorts of patients.
Our goal was to delve further in this analy-
sis by closely examining our large and homo-
geneous single-center cohort of 309 patients
with PD who underwent surgery within a
13-year period, evaluating patients before,
during, and 1 year after DBS-STN. Specifi-
cally, we wished to determine the ideal target
within the STN area that showed the greatest
improvement and fewest side effects for pa-
tients with PD. We were also interested in
which clinical and surgical factors might be
relevant for the postoperative outcome with
DBS-STN. We assessed the link between the
specific motor, cognitive, and psychiatric out-
comes after surgery and the preoperative PD
clinical features, MRI measures, surgical pro-
cedure, and locations of stimulating contacts
that might help us to define the best target
for a given patient.
METHODS Patients. Between February 1996 and July 2009,
309 patients with PD underwent DBS-STN at the Pitié-
Salpêtrière Hospital (Paris, France). Patients were deemed
suitable for surgery according to the following criteria9: (1) age
younger than 70 years (mean age: 54.8 6 8.8 years, except in 9
patients); (2) a severe form of the disease (Hoehn and Yahr stage
$2.5); (3) .40% decrease in motor symptoms with levodopa
treatment; and (4) presence of disabling levodopa-induced motor
complications despite optimal medical treatment. Exclusion
criteria included dementia, ongoing psychiatric disturbances,
surgical contraindications, and relevant brain lesions detected
on MRI.
Standard protocol approvals, registrations, and patient
consents. This study received approval from the local ethics
committee, and all patients gave written informed consent to par-
ticipate in this study.
Neurosurgical procedure. Quadripolar electrodes (model
3389-28; Medtronic, Minneapolis, MN) were bilaterally
implanted, combining intraoperative microelectrode recordings
and stimulation, and connected to a subcutaneous pulse
generator (Medtronic). Stimulation measures (pulse width, fre-
quency, intensity) were adjusted using an external programmer.19
Clinical evaluation. Evaluation of patients was performed 3
months before and 1 year after surgery.9
Parkinsonian motor disability. The activities of daily living
(ADL) score (Unified Parkinson’s Disease Rating Scale [UPDRS]
part II) was assessed by patient interview in the “off ” and “on”
drug conditions.
Before surgery, the motor disability score (UPDRS part III)
was examined in the off condition, after a 12-hour interruption
of antiparkinsonian medication, and best on-drug condition
(“residual” score), after the administration of a single suprathres-
hold dose of levodopa. Four subscores were calculated: (1)
tremor, (2) rigidity, (3) akinesia, and (4) axial. After surgery, these
scores were evaluated in 4 conditions, the same day and in the
same order: (1) on stimulation (with chronic stimulation meas-
ures) and off drug; (2) off stimulation and off drug, after stimu-
lation stopped for at least 90 minutes; (3) off stimulation and on
drug, after the administration of the suprathreshold dose of levo-
dopa; and (4) on stimulation and on drug.
Cognitive status. Neuropsychological evaluation focused on
executive functions, attention, memory, and visuoconstructive
abilities,20 by using (1) the Mattis Dementia Rating Scale
(MDRS) (range: 0–144), with low scores indicating worse
cognitive performance21; (2) the “frontal score,” determined on
a 50-point scale, including the Modified Wisconsin Card Sorting
Test (scale 0–20) and verbal fluency20; and (3) the Free and Cued
Selective Reminding Test to assess memory.20
Psychiatric status. Depressive symptoms were assessed with
the Montgomery-Åsberg Depression Rating Scale (MADRS)
(range: 0–60; depression diagnosis: score .13).22 Hypomania
and major depressive disorder were examined using a behavioral
evaluation including both a semistructured psychiatric interview
based on DSM-IV criteria (Mini-International Neuropsychiatric
Inventory) and a nonstandardized psychiatric interview.23
Antiparkinsonian treatment and stimulation parameter
settings. The levodopa-equivalent dosage and stimulation
measures were also noted. Levodopa-related complications were
evaluated using the UPDRS part IV.9
MRI acquisition and analysis. MRI acquisition was per-
formed the day before surgery, with the stereotactic Leksell frame
in place, and an MRI or 3-dimensional helical tomodensitometry
was performed the following day to visualize electrode tracks and
determine contact locations.19 A voxel-based morphometric
analysis was performed on the preoperative T1 images (with no
gadolinium) to quantify changes in the gray and white matter
concentration (n 5 160 patients).
The location of electrodes was obtained using a deformable
3-dimensional histologic atlas of the basal ganglia.24,25 Within the
STN, 3 functional territories were defined, i.e., posterior-
sensorimotor (SM), intermediate-associative (AS), and anterior-
limbic parts, by analogy with tract tracing data obtained in mon-
keys.26 The contact coordinates in the normalized atlas space with
reference to the anterior commissure–posterior commissure system
were measured relative to the posterior commissure point (absolute
laterality: X; anteroposteriority: Y; depth: Z).25
Statistical analysis. Changes in scores between baseline and the
1-year follow-up were determined with respect to the same
preoperative drug condition. The relationship between the
stimulating contact coordinates and the postoperative changes
was assessed using a univariate z correlation test. The mean
coordinates of the stimulating contacts were chosen as cutoff
points to further determine the effects of contact coordinates
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on the postoperative clinical outcome by using Student t tests.
Statistical analyses were performed using the SAS statistical
software package, version 9.2 (SAS Institute Inc., Cary, NC).
The level of significance was set at p , 0.01.
Motor outcome. The role of contact location in the postop-
erative outcome between patients with bilateral stimulation of the
SM-STN, the AS-STN, or the ZI (figures 1 and 2A) was tested
using the nonparametric Kruskal-Wallis tests.
Cognitive outcome. Patients with a preoperative MDRS score
,130 were excluded from this part of the study (figure 1). Post-
operative cognitive decline was defined as a decrease more than
mean 1 1 SD in the MDRS after surgery and/or MDRS score
,130. To determine which factors differed between patients with
vs without postoperative cognitive decline, we performed Student
t tests for continuous variables and Fisher exact tests for categorical
variables.
Psychiatric outcome. Change in the MADRS score after sur-
gery was the main outcome variable. To determine which factors
differed between patients with vs without postoperative depres-
sion (MADRS score .13), we performed Student t tests for con-
tinuous variables and Fisher exact tests for categorical variables.
Pre- and postoperative data obtained in patients with postopera-
tive depression, transient hypomanic status, or no mood disorders
were compared using nonparametric Kruskal-Wallis tests. See
e-Methods on the Neurology® Web site at Neurology.org for
further details of the methods.
RESULTS Among the 309 patients with PD who
underwent bilateral STN stimulation between January
1996 and July 2009, 47 were excluded from the final
statistical analysis (figure 1). After these exclusions, we
were able to assess the effects of bilateral stimulation on
motor, cognitive, and psychiatric symptoms and the
therapeutic contact location from a total of 262 pa-
tients with PD (103 women/159 men; mean age:
57.6 6 8.1 years; mean disease duration: 12.8 6 5.1
years) (figure 1, table 1).
Contact locations. The distribution of the stimulating
contact locations is shown in figure 2. Our method
led to the right and left stimulating contacts being
bilaterally located in the posterior-SM-STN in 17
patients, the intermediate-AS-STN in 61 patients,
and the ZI in 26 patients (figure 1 and figure 2,
A and B). In 158 patients, the 2 stimulating contacts
were not bilaterally located in the same subterritory of
the STN (figure 1 and figure 2, A and B).
Motor outcome. Patients with PDwith SM- or AS-STN
stimulation showed lower residual parkinsonian motor
disability and akinesia scores (on stimulation, off
treatment) in comparison to patients with ZI
stimulation (figure 2C), with no significant difference
in preoperative features among the 3 groups (table
e-1). None of the tremor, rigidity, and axial subscores
(table e-1, figure 2C), antiparkinsonian drug treatment
(table e-1), or parameter settings (not shown) showed
significant differences.
Figure 1 Flowchart of patients evaluated in this study
AS 5 associative; MADRS 5 Montgomery-Åsberg Depression Rating Scale; MDRS 5 Mattis Dementia Rating Scale; PD 5
Parkinson disease; SM 5 sensorimotor; STN 5 subthalamic nucleus; ZI 5 zona incerta.
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The decrease in parkinsonian motor disability and
axial scores and levodopa daily dose under bilateral
DBS-STN was significantly related to the right
anterior-Y coordinate of the stimulating contact
(p , 0.01, figure 2D). The change in levodopa-
induced motor complications (UPDRS IV) was also
significantly related to both the right and left anterior-
Y coordinates of the contacts (p , 0.01, figure 2D).
Figure 2 Effects of deep brain stimulation on parkinsonian motor disability as a function of stimulating contact location
(A) Example of oneelectrode location reconstructed on the3-dimensional digitized basal ganglia atlas showing the4 stimulating contacts (blue cylinder, upper left
image). The position of each contact is seen on the axial (upper right), sagittal (lower left), and coronal (lower right) images reconstructed in the electrode plane. The
location of the stimulating contact in the sensorimotor (SM, green), associative (AS, pink), or limbic (LI, yellow) parts of the subthalamic nucleus (STN), or outside the
STN, such as in the substantia nigra (SN, black, located ventrally to the STN), the zona incerta/Forel field area (ZI, yellow, locatedmedially to the STN), or the inter-
nal capsule (IC, red, located laterally to the STN), can therefore be accurately determined. (B) Relative distribution of locations of the chronically implanted stim-
ulating contacts in the 262 patients with Parkinson disease, in the left and right hemispheres. (C) Effects of the bilateral stimulation of the SM-STN (green
columns) vs AS-STN (pink columns) vs ZI (blue columns) on parkinsonian motor disability (Unified Parkinson’s Disease Rating Scale [UPDRS] part III), rigidity,
akinesia, and axial signs 1 year after surgery (on stimulation, off drug). The first gray column represents the scores before surgery without antiparkinsonian
treatment (off drug). Asterisks indicate significant differences between groups. (D) Relationship between the anteroposterior (Y) coordinate of the right stimu-
lating contact and the improvement in motor disability with bilateral stimulation alone (on stimulation, off drug; left graph), reduction in the levodopa replacement
therapy (middle graph), and change in levodopa-induced motor complications (right graph), 12 months after surgery. CP 5 commissure posterior.
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Patients with PD who had higher Y coordinates
(.10.6 mm, right side) vs lower (#10.6 mm)
showed significantly greater improvements in motor
disability and decreases in levodopa-induced motor
complications and levodopa daily dose (p , 0.01)
(figure e-1).
Cognitive outcome. The MDRS score was significantly
lower after surgery (table 1), with 18% of patients
showing a decrease of .6 points (n 5 31) and/or
an MDRS score ,130 (n 5 14) (figure 1). Patients
with postoperative cognitive decline showed greater
decreases for all of the cognitive domains explored
(except the visuoconstructive test) and higher scores
for ADL, motor disability, and akinesia scores (figure
3A, table e-2). Preoperative clinical features and brain
MRI white and gray matter densities (voxel-based
morphometry) showed no significant differences
between the 2 groups (table e-2). Perioperative con-
fusion and psychosis were more frequent in patients
who went on to develop a cognitive decline (24% vs
6%, p , 0.001) (table e-3).
The stimulating contacts were located differently
in the 2 groups, with a more frequent position within
Table 1 UPDRS scores, cognition, depression, and dopaminergic drug treatment
Baseline 12 mo
Change between
baseline and 12 mo p
UPDRS
Part II: ADL
Off treatment 21.6 (7.8) 11.4 (6.4) 210.3 (211.4 to 29.2) ,1024a
On treatment 6.6 (5.4) 8.2 (5.6) 1.6 (0.8–2.4) 0.0001a
Part III: motor
Off treatment 38.7 (14.3) 14.8 (9.5) 223.9 (225.8 to 222.2) ,1024a
On treatment 9.3 (7.2) 7.5 (6.0) 21.7 (21.0 to 22.4) ,1024a
Part III: akinesia
Off treatment 18.3 (6.8) 8.1 (5.6) 210.3 (211.2 to 29.4) ,1024a
On treatment 4.9 (4.1) 4.1 (3.8) 20.6 (21.1 to 20.1) 0.023
Part III: rigidity
Off treatment 7.8 (4.1) 2.1 (2.4) 25.7 (26.2 to 25.2) ,1024a
On treatment 1.7 (2.5) 1.0 (1.5) 20.7 (21.0 to 20.4) ,1024a
Part III: tremor
Off treatment 5.0 (5.1) 1.3 (2.2) 23.7 (24.3 to 23.1) ,1024a
On treatment 0.5 (1.2) 0.3 (0.8) 20.2 (20.4 to 0.0) 0.002a
Part III: axial signs
Off treatment 7.5 (4.1) 3.4 (2.8) 24.2 (24.7 to 23.7) ,1024a
On treatment 2.2 (2.2) 2.2 (2.1) 20.1 (20.4 to 0.2) 0.70
Part IV: levodopa-related complications 9.3 (3.5) 2.4 (2.4) 26.8 (27.3 to 26.3) ,1024a
Antiparkinsonian drug treatment
Levodopa dosages, mg/d 889 (373) 243 (278) 2648 (2696 to 2600) ,1024a
Dopamine agonist dosage, mg/d 320 (286) 128 (190) 2191 (2227 to 2155) ,1024a
Cognition-depression
Global cognition, MDRS 138.5 (5.1) 137.2 (7.7) 21.2 (22.0 to 20.4) 0.002a
mWCST 16.5 (4.4) 16.6 (4.5) 0.0 (20.5 to 0.5) 0.85
Frontal score 43.1 (7.0) 42.4 (7.1) 20.5 (21.3 to 0.3) 0.15
Depression, MADRS 8.2 (5.5) 8.2 (7.0) 20.5 (21.7 to 0.7) 0.46
Abbreviations: ADL 5 activities of daily living; MADRS 5 Montgomery-Åsberg Depression Rating Scale; MDRS 5 Mattis
Dementia Rating Scale; mWCST 5 modified Wisconsin Card Sorting Test; UPDRS 5 Unified Parkinson’s Disease Rating
Scale.
Data are mean (SD). UPDRS score ranges: ADL 0–52, motor 0–108, akinesia 0–40, rigidity 0–20, tremor 0–28, axial signs
0–20, and levodopa-related complications 0–44 (high scores 5 worse clinical assessment of the patient’s Parkinson dis-
ease). Cognition score ranges: MDRS 0–144, mWCST 0–20, and frontal score 0–50 (high scores 5 better cognitive
function). Depression: MADRS 0–60 (high score 5 worse depressive signs).
a Significant differences.
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Figure 3 Postoperative parkinsonian disability and stimulating contact location in PD patients with vs without cognitive decline 1 year after
surgery
(A) Differences in parkinsonian activities of daily living (UPDRS part II), motor disability (UPDRS part III), and axial motor sign scores with bilateral subthalamic
stimulation alone (OFF, solid red bars) or with drug (ON, empty red bars) in patients with PD who had postoperative cognitive decline (left panel) vs cognitive
stability (right panel). The first bars (gray) represent the results obtained for the same scores in the off-drug condition before surgery in each group. (B) Location
of the stimulating contacts of the patients with PD who had postoperative cognitive decline (left panel, red cylinders) vs cognitive stability (right panel, blue cyl-
inders). The graph represents the relative proportion of stimulating contacts locatedwithin the different subthalamic subregions (sensorimotor, associative, and
limbic) and surrounding areas (zona incerta/Forel field, internal capsule, substantia nigra pars reticulata). (C) Changes in themeanMDRSscore in PDpatientswith
(filled red squares) vswithout (black squares) cognitive decline, 1 and2 years after surgery. Note that in both groups cognitive status did not significantly change
between the first and the second year postsurgery. (D) Relationship between the anteroposterior (Y) coordinate of the right stimulating contact and the change in
the frontal score (left panel) and category verbal fluency (middle panel), and the depth (Z) of the right stimulating contact and the change in theMDRSscore (right
panel). Asterisks indicate significant differences between the 2 groups. CP 5 commissure posterior; MDRS 5 Mattis Dementia Rating Scale; PD 5 Parkinson
disease; STN 5 subthalamic nucleus; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
Neurology 82 April 15, 2014 1357
the STN in patients with postoperative cognitive
decline, and within the ZI in patients with no decline
(for the right side, figure 3B). In patients with cogni-
tive decline vs without, the left stimulating contacts
were located more posteriorly and deeper. A signifi-
cant positive relationship was found between both the
left and right anterior-Y coordinates of the stimulat-
ing contacts and the changes in the “frontal,” verbal
fluency (category and phonemic), and free-recall
scores (figure 3D). Patients with PD who had a high-
er right Y coordinate (.10.6 mm) vs lower (#10.6
mm) had significant higher scores for verbal fluency,
with a smaller decrease in the frontal and verbal flu-
ency scores (p , 0.01, not shown). The left anterior-
Y coordinate was also positively correlated with the
changes in the initiation and memory scores (MDRS,
p , 0.01, not shown) and patients with higher left Y
coordinates showed significantly less decrease in the
MDRS score after surgery (p , 0.01, not shown).
The right and left depth (Z) coordinates were also
significantly related to the change in the memory-
MDRS score (figure 3D), with a smaller decrease in
patients with a lower right Z coordinate (not shown).
No difference in the stimulation measures was found
between groups (not shown).
Psychiatric outcome. Before surgery, 45 patients showed
symptoms of depression. The mean MADRS score did
not change significantly after surgery (table 1). Eighty-
four patients showed no postoperative mood disorders,
26 of 45 depressive patients improved their mood
status, and 27 developed depression (figure 1). No
significant difference was found between patients
who went on to develop or maintain depressive signs
after surgery (n 5 46) vs patients whose depression
improved (n 5 26), except for lower pre- and
postoperative cognitive scores in depressive patients
(p , 0.006). No significant difference was found for
the parameter settings or contact locations between
groups.
Nineteen patients presented with transient hypo-
mania in the perioperative period, relieved by modify-
ing stimulation parameter settings and/or medication
(figure 1). This group of patients had (1) younger age,
(2) shorter disease duration, and (3) similar severity of
parkinsonian motor disability (off treatment) with
fewer residual motor signs with dopaminergic drug
treatment (figure 4) and MADRS score (not shown).
After surgery, these patients also showed lower ADL
(on treatment) and MADRS scores. No significant
difference was found for the parameter settings
between groups, but the mean coordinates of contacts
inducing hypomania were found to be significantly
deeper with a more frequent position in the
intermediate-AS-STN (53% vs 31%) and the SN
(8% vs 1.5%), and less frequently in the ZI (3% vs
13%) (p 5 0.009, figure 4). See e-Results for further
details of the results.
DISCUSSION In this large single-center cohort of
highly selected patients with PD who underwent
bilateral STN-DBS, we showed that (1) the most
effective target for the alleviation of PD motor
symptoms and levodopa-induced motor complications
is the STN and not the surrounding structures, (2)
the occurrence of postoperative cognitive decline is
mainly related to the surgical procedure, with
stimulation sites associated with memory decline
being located more ventral, and (3) stimulation-
induced hypomania is related to both the form of the
disease and deeper contact locations, whereas
postoperative depression was only found to be related
to preexisting depressive signs and lower cognitive
performance.
To determine whether or not bilateral STN stim-
ulation performed under the “best” conditions with
the best patient candidates might be deleterious, this
study was conducted in a large homogeneous popu-
lation of patients with PD selected using strict inclu-
sion criteria. In consequence, the influence of
preoperative features (age, levodopa responsiveness,
and preoperative cognitive status) on the postopera-
tive outcome could have been masked, at least in part.
The role of the contact locations was examined by
using a deformable atlas that provides a 1-mm preci-
sion,25 and functional STN subdivisions were ob-
tained from track tracings in monkeys.26 Recent
neurophysiologic and imaging studies performed in
healthy subjects and patients with PD suggest that a
similar STN functional organization exists (posterior-
SM, intermediate-AS, and anterior-limbic).11,27,28
This objective evaluation of stimulation sites has also
been applied by other teams29 and in multicenter
clinical research protocols.30 The electrode locations
in our patients were most frequently located within
the intermediate-AS part of the STN, with only a
small number of bilateral locations in the posterior-
SM-STN. This probably results from our presurgical
planning that targeted the center of the STN19 with a
trajectory that provides better intraoperative electro-
physiologic recordings and acute clinical effects, espe-
cially alleviation of akinesia.31
For such a large population of patients, the effect of
DBS-STN on parkinsonian motor symptoms can be
considered dramatic as judged by the 64% improve-
ment in motor disability with stimulation alone. Such
improvement is greater than that reported by others
using less restrictive inclusion criteria.6,7 This argues
for the strict selection of patients to obtain the best
motor outcome with minimum side effects.
The effects on parkinsonian disability showed no
difference whether stimulation was performed within
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the posterior-SM or intermediate-AS parts of the
STN, with the best motor improvements found with
the most anterior electrode locations (closer to the
associative part of the STN; figure 2, C and D). This
suggests that stimulation of the intermediate-AS part
of the STN represents a preferential location to
improve parkinsonian motor akinesia.18 However,
other authors have proposed a more dorsoposterior
target within the STN,32 where the most powerful b
oscillatory activity is recorded and correlated with best
motor improvement.33 This apparent discrepancy
may be explained by the following facts: (1) the entire
volume of the STN receives afferent projections from
the motor cortex via the “hyperdirect pathway,”
whose activity is modulated by STN stimulation
and related to the motor effects of this treatment34;
(2) motor and associative territories of the STN are
separated by functional gradients,26 suggesting that
neurons in the central part of the STN may have
connections with both SM and AS inputs; and (3)
the somatotopic organization of the STN neurons in
patients with PD is partly lost.35 However, akinesia
comprises motor but also cognitive and motivational
components, understandably improved by targeting
the associative neuronal network. Stimulation of the
ZI area gave poorer motor improvement (49%) with
no evidence of a specific effect on tremor severity, as
previously reported.8
Chronic stimulation of the associative STN
induced no decline in executive functions, in contrast
to acute stimulation27 or in patients with low cogni-
tive capacity,4 and more anterior stimulation (close to
the associative STN) was related to an increase in
executive function 1 year after surgery. This is in line
with anterior positioning of electrodes reported in
patients with PD showing no decline in mental status
scores after surgery.14 Ventral electrode location was
found to be associated with memory decline, as pre-
viously observed.36 However, the fact that patients
with PD who had a 1-year postoperative decline
Figure 4 Psychiatric effects of deep brain stimulation in patients with PD as a function of age, disease characteristics, postoperative motor
disability improvement, and stimulating electrode locations
(A) Differences in age at time of surgery, disease duration, parkinsonian motor disability “on” drug before surgery and “on” stimulation alone after surgery in
patients with Parkinson disease (PD) who had postoperative depression (blue bars), hypomanic episodes (red bars), or no mood disorders (black bars). (B) Left
panel: stimulating contacts used in patients with PDwho had postoperative depression (blue cylinders) or hypomania (brown cylinders); right panel: mean (SD)
X, Y, and Z coordinates in the anterior commissure–posterior commissure space of the stimulating contacts in patients with PD who had postoperative
depression or hypomania. Asterisks indicate significant differences between groups.
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showed no further cognitive decline 2 years after sur-
gery (figure 2C) suggests that the main factor related
to its occurrence is the surgical procedure creating a
microlesion.15 Facts supporting this hypothesis are
that (1) an acute decline in some executive functions
is observed in the days after surgery37 or in the
absence of STN stimulation,38 and (2) similar cogni-
tive side effects exist, whatever the surgical target, i.e.,
the STN or the globus pallidus interna.6,7,38
Stimulation of the more ventral (limbic) part of
the STN induced hypomania, as previously reported
in both patients with PD11,12 and patients with psy-
chiatric disorders.30 Hypomania was mainly observed
in younger patients, those with shorter disease dura-
tion, and those with a higher levodopa responsive-
ness, i.e., a disease profile similar to that observed
in patients with dopaminergic dysregulation.39 Con-
versely, postoperative depression was not found to be
related to electrode location, but to the presence of a
preoperative depression, parkinsonian mental deficit,
and axial motor signs, as previously reported.40
The STN, therefore, and not the surrounding
areas, appears to be the ideal target to improve motor
disability in patients with PD. This technique may
provoke memory or emotional disturbances, espe-
cially if the electrodes are too ventral in the STN. This
confirms the role of the STN in motor and nonmotor
processing and its possible importance in nonmotor
diseases.
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